Shore Capital Reiterates Buy Rating for Life Science REIT (LON:LABS)

Life Science REIT (LON:LABS)‘s stock had its “buy” rating reiterated by equities research analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat.com reports.

Separately, Jefferies Financial Group reduced their target price on Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a “hold” rating on the stock in a report on Friday, August 30th.

Life Science REIT Trading Up 8.2 %

LON LABS opened at GBX 37 ($0.50) on Thursday. The company has a market capitalization of £129.50 million, a price-to-earnings ratio of -621.00 and a beta of 0.08. Life Science REIT has a 1-year low of GBX 31.30 ($0.42) and a 1-year high of GBX 74.20 ($0.99). The stock’s 50 day moving average is GBX 33.45 and its two-hundred day moving average is GBX 36.01.